our investments
155 Grants We've Funded
| Year | Amount | Center | Researcher | Grant Name | Category | Type of Cancer |
|---|---|---|---|---|---|---|
| 2025 | $225,500.00 | Children's Oncology Group | ||||
| 2025 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Kristopher Bosse | GPC2 CARs and dinutuximab: synergizing dual antigen targeting and adaptive and innate antitumor immunity via blocking the GD2-siglec-7 inhibitory axis in neuroblastoma. | Solid and Bone Cancers | Neuroblastoma |
| 2025 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mosse | Identifying and Targeting Epigenomic Mechanisms of Resistance in Neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2025 | $100,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Functional characterization and armoring of peptide-centric CAR T cells to enhance efficacy | Solid and Bone Cancers | Neuroblastoma |
| 2025 | $200,000.00 | Dana-Farber Cancer Institute | Dr. Yana Pikman | Targeting MAT2A for novel T-cell acute lymphoblastic leukemia therapy. | Blood Cancer | Leukemia |
| 2025 | $200,000.00 | Seattle Children's Hospital | Dr. Jack Brzezinski | Enhanced Wilms tumor diagnosis, risk stratification, and surveillance through cell free DNA methylation | Solid and Bone Cancers | Wilms Tumor |
| 2025 | $200,000.00 | Seattle Children's Hospital | Dr. Nicholas Vitanza | B7-H3-targeting myeloid cells against diffuse midline glioma | Brain Tumors | Diffuse Midline Glioma |
| 2025 | $100,000.00 | Seattle Children's Hospital | Dr. James Olson | Antigen Assimilating Multispecific T Cell Engagers (MTEs) for the Treatment of Diffuse Midline Glioma (DMG) | Brain Tumors | Diffuse Midline Glioma |
| 2025 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Alejandro Gutierrez | Defining and Targeting PI3Kgamma-Mediated Asparaginase Resistance in T-Cell Acute Lymphoblastic Leukemia | Blood Cancer | Leukemia |
| 2025 | $200,000.00 | Texas Children's Cancer Center | Dr. David Steffan | Armored GPC3-CAR T cells for children with treatment refractory Atypical Teratoid Rhabdoid Tumors | Brain Tumors | Atypical Teratoid Rhabdoid Tumors |
| 2025 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Elliot Stieglitz | Preclinical Evaluation of Direct RAS Inhibition in Juvenile Myelomonocytic Leukemia | Blood Cancer | Leukemia |
| 2025 | $100,000.00 | UCSF Benioff Children's Hospital | Dr. Ross Okimoto | Exploiting DNA repair mechanisms to overcome CIC-DUX4 sarcoma | Solid and Bone Cancers | Sarcoma |
| 2024 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Arun Wiita | Optimized anti-CD70 CAR-NK cells for the treatment of pediatric Acute Myeloid Leukemia | Blood Cancer | Leukemia |
| 2024 | $350,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Meena Hedge | Multi-center clinical testing of autologous HER2 CAR T cells and its synergy with surgical resection in recurrent ependymoma | Brain Tumors | Ependymoma |
| 2024 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Developing cytokine-armed CAR-NKT immunotherapy for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2024 | $125,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Defining cell(s) of origin and clinical risk in Langerhans cell histiocytosis | Blood Cancer | Langerhans cell histiocytosis |
| 2024 | $125,000.00 | St. Jude Children's Research Hospital | Dr. Sara Federico | HuNB803: A Safety Run-in and Phase 2 Randomized Trial of Chemoimmunotherapy Administered With or Without N-803, A Novel IL-15 Superagonist, for the Treatment of Patients With Relapsed or Refractory Neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2024 | $200,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. Mingon Loh | Testing an Immunotherapy Drug/Molecule for Dual Recognition and Attachment to CD19 and CD33 Markers on MPAL Cancer Cells | Blood Cancer | Leukemia |
| 2024 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Jason Lewis | Radiotherapeutic Targeting of Developmental Mutators in Childhood Solid Tumors As a Prelude to a New Clinical Trial for Children with Neuroblastomas and Other DLL3 Solid Tumors | Solid and Bone Cancers | Neuroblastoma |
| 2024 | $200,000.00 | Daba-Farber Cancer Institute/Jimmy Fund | Dr. Thomas Look | Developing cytokine-armed CAR-NKT immunotherapy for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2024 | $224,000.00 | Children's Oncology Group | ||||
| 2023 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Ross Okimoto | Exploiting DNA repair mechanisms to overcome CIC-DUX4 sarcoma | Solid and Bone Cancers | Sarcoma |
| 2023 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Philip Lupo | Outcomes and Health Risks among Individuals with Genetic Predispositions to Cancer: The ORIGen Study | ||
| 2023 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Meena Hedge | Multi-center clinical testing of autologous HER2 CAR T cells and its synergy with surgical resection in recurrent ependymoma | Brain Tumors | Ependymoma |
| 2023 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Elizabeth Stewart | Evaluation of PARP1 selective inhibitor AZD5305 in combination with DNA damaging agents in Ewing sarcoma | Solid and Bone Cancers | Ewing sarcoma |
| 2023 | $200,000.00 | Seattle Childrens Hospital/Fred Hutchinson Cancer Research Center | Dr. Jim Olson | Antigen Assimilating Multispecific T Cell Engagers (MTEs) for the Treatment of Diffuse Midline Glioma (DMG) | Brain Tumors | Diffuse midline glioma (DMG) |
| 2023 | $200,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Enhancing the efficacy of GD2 Cancer Vaccine for high-risk neuroblastoma by augmenting seroconversion | Solid and Bone Cancers | Neuroblastoma |
| 2023 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Scott Armstrong | Targeting Chromatin Complexes in NUP98-rearranged AML | Blood Cancer | Leukemia |
| 2023 | $276,500.00 | Children's Oncology Group | ||||
| 2023 | $200,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Functional characterization and armoring of peptide-centric CAR T cells to enhance efficacy | Solid and Bone Cancers | Neuroblastoma |
| 2022 | $150,000.00 | UCSF Benioff Children's Hospital | Dr. E. Alejandro Sweet-Cordero | Targeting the DNA damage response pathway to treat metastatic osteosarcoma | Solid and Bone Cancers | Osteosarcoma |
| 2022 | $150,000.00 | UCSF Benioff Children's Hospital | Dr. Elliot Stieglitz | CLL-1 CAR-T cells for the treatment of JMML | Blood Cancer | Leukemia |
| 2022 | $150,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Robin Parihar | Development of a human natural killer cell immunotherapy against pediatric sarcomas | Solid and Bone Cancers | Sarcoma |
| 2022 | $59,367.34 | Memorial Sloan-Kettering Cancer Center | Dr. Brian Kushner | Phase II Study of Humanized 3F8 Anti-GD2 Monoclonal Antibody and GM-CSF in Patients with Refractory or Relapsed High-Risk Neuroblastoma | Solid and Bone Cancer | Neuroblastoma |
| 2022 | $150,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Christopher Klebanoff | Therapeutic targeting of a recurrent fusion-derived "public" neoantigen expressed by pediatric desmoplastic small round cell tumors using T cell receptor (TCR) gene therapy | Solid and Bone Cancers | Sarcoma |
| 2022 | $150,000.00 | Childrens Hospital of Philadelphia | Dr. John Maris | Developing a warehouse of peptide-centric CARs for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2022 | $206,500.00 | Children's Oncology Group | ||||
| 2022 | $150,000.00 | St. Jude Children's Research Hospital | Dr. Stephen Mack | The activity of combined epigenetic and immune checkpoint inhibition in H3K27me3 deficient brain tumors | Brain Tumors | |
| 2022 | $150,000.00 | St. Jude Children's Research Hospital | Dr. Stephen Gottschalk | CD70-directed CAR T-cell therapy for the treatment of relapsed/refractory pediatric AML | Blood Cancer | Leukemia |
| 2021 | $143,500.00 | Children's Oncology Group | ||||
| 2021 | $150,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Testing Depletion of Pathogenic Cells in Langerhans Cell Histiocytosis | Blood Cancer | Langerhans cell histiocytosis |
| 2021 | $150,000.00 | St. Jude Children's Research Hospital | Dr. Jiyang Yu | Combination Therapy Targeting Hidden Drivers in MYC-driven Medulloblastoma | Brain Tumors | Medulloblastoma |
| 2021 | $150,000.00 | Children's Hospital Of Philadelphia | Dr. John Maris | Developing a warehouse of peptide-centric CARs for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2021 | $150,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Christopher Klebanoff | Therapeutic targeting of a recurrent fusion-derived "public" neoantigen expressed by pediatric desmoplastic small round cell tumors using T cell receptor (TCR) gene therapy | Solid and Bone Cancers | Sarcoma |
| 2021 | $150,000.00 | UCSF Benioff Children's Hospital | Dr. Kevin Shannon | Co-targeting Raf and MEK in Pediatric Acute Myeloid Leukemia | Blood Cancer | Leukemia |
| 2020 | $50,000.00 | Seattle Childrens Hospital/Fred Hutchinson Cancer Research Center | Dr. Nicholas Vitanza | Advanced molecular monitoring of CAR T cell therapy for diffuse midline gliomas | Brain Tumors | Diffuse midline gliomas (DMG) |
| 2020 | $150,500.00 | Children's Oncology Group | ||||
| 2020 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Rani George | Augmenting immune response in neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2020 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Robin Parihar | Development of a human natural killer cell immunotherapy against pediatric sarcomas | Solid and Bone Cancers | Sarcoma |
| 2020 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Yustein | Targeting PAK4 in high-risk rhabdomyosarcoma | Solid and Bone Cancers | Rhabdomyosarcoma |
| 2020 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Martine F Roussel | Targeting the p53 pathway in high risk pediatric atypical teratoid rhabdoid tumors | Solid and Bone Cancers | Rhabdoid Tumors |
| 2020 | $100,000.00 | UCSF Benioff Children's Hospital | Dr. Ernesto Diaz-Flores | Exploiting therapeutic opportunities against high-risk leukemias harboring TP53 mutations | Blood Cancer | Leukemia |
| 2020 | $100,000.00 | Children's Hospital Of Philadelphia | Dr. Kathrin M. Bernt | Understanding mechanisms and developing therapies for MN1-driven leukemia | Blood Cancer | Leukemia |
| 2019 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Clay Gustafson | Translating combinationtherapy of Aurora Kinase A inhibition with the targeted radiopharmaceutical 131IMIBG in neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2019 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Robin Parihar | Development of a human natural killer cell immunotherapy against pediatric sarcomas | Solid and Bone Cancers | Sarcoma |
| 2019 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stephen Mack | The activity of combined epigenetic and immune checkpoint inhibition in H3K27me3 deficient brain tumors | Brain Tumors | |
| 2019 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Brandon Triplett | Allogeneic CD19-CAR T cells for ALL | Blood Cancer | Leukemia / Lymphoma |
| 2019 | $100,000.00 | Seattle Childrens Hospital/Fred Hutchinson Cancer Research Center | Dr. Marie Bleakley | Immunotherapy for Infant Leukemia - Extension Application | Blood Cancer | Leukemia |
| 2019 | $200,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Michael Ortiz | A multi-center phase I study of codrituzumab in pediatric patients with relapsed or refractory glypican 3 (GPC3) expressing extra-cranial solid tumors | Solid and Bone Cancers | Hepatoblastoma, Wilms tumor, rhabdoid tumors, germ cell tumors |
| 2019 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Brigit Knoechel | Targeting Galectin-9 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia | Blood Cancer | Leukemia / Lymphoma |
| 2019 | $143,500.00 | Children's Oncology Group | ||||
| 2019 | $200,000.00 | Children's Hospital Of Philadelphia | Dr. Andrei Thomas-Tikhonenko | Novel chenoimmunotherapeutics for B-lymphoid childhood malignancies | Blood Cancer | Leukemia/Lymphoma |
| 2019 | $150,000.00 | Children's Hospital Of Philadelphia | Dr. Yael Mosse | Clinical Development of Next Generation ALK inhibitor lorlatinib for patients with ALK-driven neuroblastomas | Solid and Bone Cancers | Neuroblastoma |
| 2018 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. E. Alejandro Sweet-Cordero | Genome-informed therapy for osteosarcoma | Solid and Bone Cancers | Osteosarcoma |
| 2018 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Andras Heczey | T cells expressing an optimized Glypican-3-specific CAR for children with solid tumors. | Solid and Bone Cancers | Hepatoblastoma, Wilms tumor, rhabdoid tumors, germ cell tumors |
| 2018 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Redefining Standard of Care for Front-Line Therapy for Langerhans Cell Histiocytosis | Blood Cancer | Langerhans cell histiocytosis |
| 2018 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Kim Kramer | Radioimmunotherapy with Intraventricular 131I-hu3F8 for CNS Malignancies | Brain Tumor | Medulloblastoma |
| 2018 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Steven DuBois | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | General Pediatric Cancer | |
| 2018 | $274,300.00 | Chilldren's Oncology Group | ||||
| 2017 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Mignon Loh | Identifying Targeted Therapeutics in Juvenile Myelomonocytic Leukemia | Blood Cancer | Leukemia |
| 2017 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Cliona Rooney | VZV Vaccination to enhance the activity of GD2.CAR-modified, VZV-specific T-cells against neuroblastoma and osteosarcoma. | Solid and Bone Cancers | Neuroblastoma & Osteosarcoma |
| 2017 | $185,221.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Generation of cGMP grade antigen-presenting cells for NKT-cell expansion | Solid and Bone Cancers | Neuroblastoma |
| 2017 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Meenakshi Hegde | Phase 1 trial of autologous HER2-CAR T cells after lymphodepletion for HER2-positive solid tumors in children | Solid and Bone Cancers | Osteosarcoma, gliomas, sarcomas |
| 2017 | $200,000.00 | Seattle Childrens Hospital/Fred Hutchinson Cancer Research Center | Dr. Marie Bleakley | Immunotherapy for Infant Leukemia | Blood Cancer | Leukemia |
| 2017 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Alex Kentsis | Control and therapy of genome integrity in medulloblastoma | Brain Tumors | Medulloblastoma |
| 2017 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Study of Biologic Correlates in a Phase I/II study of humanized 3F8 bispecific antibody (Hu3F8-BsAb) in patients with relapsed/refractory neuroblastoma, osteosarcoma, and other GD2(+) solid tumors | Solid and Bone Cancers | Neuroblastoma, Osteosarcoma |
| 2017 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Kimberly Stegmaier | Discovering Novel Drug Combinations with CDK4/6 Inhibitors in Pediatric Cancer | General Pediatric Cancer | |
| 2017 | $200,000.00 | Children's Hospital of Philadelphia | Dr. David T. Teachey | Enhancing Chimeric Antigen Receptor efficacy by limiting toxicity | Blood Cancer | Leukemia |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Shohet | A Safety Pilot Study of High Risk Induction Chemotherapy for Neuroblastoma without Prophylactic Administration of Myeloid Growth Factors (SPRING). | Solid and Bone Cancers | Neuroblastoma |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Ann Leen | Adoptive T-cell therapy for ALL targeting multiple tumor associated antigens | Blood Cancers | Leukemia |
| 2016 | $407,269.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Andras Heczey | T cells expressing an optimized Glypican-3- specific CAR for children with solid tumors | Solid and Bone Cancers | Hepatoblastoma, Wilms tumor, rhabdoid tumors, germ cell tumors |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Ronald Bernardi | Combined inhibition of WEE1 and oncogenic receptor tyrosine kinases as a therapeutic strategy to overcome redundant mitotic checkpoint control in neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Correlative Biology to Predict Response and Toxicity in Children Receiving Immunotherapy and Cytotoxic T Cell Therapy for Post- Transplant Lymphoproliferative Disease | Blood Cancer | |
| 2016 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Sara Federico | A pilot induction regimen incorporating dinutuximab for the treatment of newly diagnosed high-risk neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2016 | $200,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Brian Kushner | Phase II Study of Humanized 3F8 Anti-GD2 Monoclonal Antibody and GM-CSF in Patients with Refractory or Relapsed High-Risk Neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2016 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Nicholas Haining | Discovering somatic mutations in cancer that cause resistance to immunotherapy | General Pediatric Cancer | |
| 2016 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Scott Armstrong | New combination therapies for MLL-rearranged Acute Lymphoblastic Leukemia | Blood Cancer | Leukemia / Lymphoma |
| 2016 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mosse | Clinical Development of Next Generation ALK inhibitor lorlatinib for patients with ALK-driven neuroblastomas | Solid and Bone Cancers | Neuroblastoma |
| 2016 | $2,200.00 | Children's Hospital of Philadelphia | Dr. Michael Hogarty | LCH-CLO Trial | Blood Cancer | Langerhans cell histiocytosis |
| 2016 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Carolyn Felix | Ribavirin-Epigenetic Therapy Combinations to Combat MLL-R Infant ALL | Blood Cancer | Leukemia / Lymphoma |
| 2015 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Shohet | Characterization and targeting of neuroblastoma Cancer Stem Cells (CSCs) | Solid and Bone Cancers | Neuroblastoma |
| 2015 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Donald Parsons | Evaluating the Impact of Tumor Heterogeneity and Clonal Evolution on Clinical Genomic Testing for Pediatric Solid Tumor Patients | Solid and Bone Cancers | |
| 2015 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Redefining Standard of Care for Front-line Therapy for Langerhans Cell Histiocytosis (LCH) | Blood Cancer | Langerhans cell histiocytosis |
| 2015 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Nabil Ahmed | Adoptive Immunotherapy for Pediatric Sarcoma | Solid and Bone Cancers | Sarcoma |
| 2015 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Jeffrey Rubnitz | Pilot study of microtransplantation in pediatric patients with refractory or relapsed acute myeloid leukemia | Blood Cancer | Leukemia |
| 2015 | $50,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Shakeel Modak | Targeting Pediatric Solid Tumors: A Pilot Study of RadioImmuno-PET Imaging using I-Humanized 3F8 | Solid and Bone Cancers | Neuroblastoma |
| 2015 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Shakeel Modak | The development and preclinical validation of site-specifically radiolabeled hu3F8 for PET Imaging and radioimmunotherapy of neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2015 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Kim Kramer | A phase I study of convection-enhanced delivery of 124I-8H9 for patients with non-progressive diffuse pontine gliomas (DIPG) previously treated with external beam radiation therapy | Brain Tumors | Diffuse intrinsic pontine glioma (DIPG) |
| 2015 | $150,000.00 | Children's Oncology Group | Dr. Michael LaQuaglia | Prospective study of outcomes after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis | Solid and Bone Cancers | Osteosarcoma |
| 2015 | $500,000.00 | Children's Oncology Group | Full payment for $4k per child enrolled in 2015 to COG's Phase 1 Clinical Trial Consortium. 2x the Federal Government's per child allocation | |||
| 2015 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mose | Preclinical and Clinical Development of Next Generation ALK Inhibitor, PF-06463922, or ALK driven neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2014 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Peter Zage | A Phase I Study of vandetanib (CaprelsaTM) in combination with 13-cis-retinoic acid in children with relapsed or refractory solid tumors | Solid and Bone Cancers | |
| 2014 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stephen Gottschalk | IL13Ra2-CAR T-cell therapy for pediatric high grade glioma | Brain Tumors | High-grade glioma |
| 2014 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Charles Mullighan | Identifying novel drivers and childhood acute lymphoblastic leukemia disease and resistance | Blood Cancer | Leukemia / Lymphoma |
| 2014 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Shakeel Modak | Targeting pediatric solid tumors: A pilot study of Radiolmmuno-PET imaging using 124I-Humanized 3F8 | Solid and Bone Cancers | Neuroblastoma |
| 2014 | $150,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Brian Kushner | Bivalent vaccine plus beta-glucan for high-risk neuroblastoma in first remission | Solid and Bone Cancers | Neuroblastoma |
| 2014 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bispecific T-Cell Engaging (BiTE) Antibody to Target Neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2014 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Jerome Ritz/Dr. Glenn Dranoff | A Phase I Study of irradiated GM-CSF secreting autologous neuroblastoma cell vaccine (GVAX) for relapsed or refractory neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2014 | $150,000.00 | Children's Oncology Group | Dr. Michael LaQuaglia | Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *Second year of 3-year project totaling $450,000. | Solid and Bone Cancers | Osteosarcoma |
| 2014 | $700,000.00 | Children's Oncology Group | ||||
| 2014 | $200,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Identifying novel drug combinations for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2014 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Richard Aplenc | Chimeric antigen receptor T cell immunotherapy for pediatric acute myeloid leukemia | Blood Cancer | Leukemia |
| 2013 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Phase I clinical trial of a novel immune therapy using dual-specific Nkt cells for children with neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2013 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stacey Berg | Phase I trial of Sgt-53, a novel nanoparticle therapy, for children with refractory or recurrent solid tumors | Solid and Bone Cancers | |
| 2013 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Hiroto Inaba | Genetic characterization and therapeutic targeting of pediatric mixed phenotype acute leukemia | Blood Cancer | Leukemia |
| 2013 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Retargeting t cells using bispecific antibody against receptor Tyrosine Kinase-like orphan receptors 2 (Ror2) in solid tumors | Solid and Bone Cancers | |
| 2013 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Kimberly Stegmaier | New treatments for neuroblastoma by targeting the Epigenome | Solid and Bone Cancers | Neuroblastoma |
| 2013 | $150,000.00 | Children's Oncology Group | Dr. Michael LaQuaglia | Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *First year of 3-year project totaling $450,000. | Solid and Bone Cancers | Osteosarcoma |
| 2013 | $352,000.00 | Children's Oncology Group | Matching federal funds per child enrolled in Phase I clinical trials | |||
| 2013 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Thomas-Tikhonenko | Decreasing resistance to chemotherapies in pediatric lymphomas, and decreasing sensitivities and effects related to the chemotherapy drug Doxorubicin | Blood Cancer | Lymphoma |
| 2013 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Kim Nichols | Novel cell-based therapy for b cell leukemias and lymphomas | Blood Cancer | Leukemia / Lymphoma |
| 2012 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stephen Gottschalk | Fap-targeted t cell therapy for osteosarcoma | Solid and Bone Cancers | Osteosarcoma |
| 2012 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Wayne Furman | Hu14.18322a + Multi-Modality treatment for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2012 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Dual specific human monoclonal antibody targeting IGF-I and IGF-II for pediatric cancers | Solid and Bone Cancers | Neuroblastoma |
| 2012 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Kim Kramer | Delivery of 124-I-8h9 non-progressive diffuse Pontine Gliomas | Brain Tumors | Diffuse intrinsic pontine glioma (DIPG) |
| 2012 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Barbara Degar/Dr. Carlos Rodriguez-Galindo | Phase II study of clofarabine in refractory Langerhans cell histiocytosis | Blood Cancer | Langerhans cell histiocytosis |
| 2012 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Suzanne Shusterman | Csf producing whole tumor vaccine for neurblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2012 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Roberts | Targeting of Cdk4 signaling in pediatric Rhabdoid tumors | Solid and Bone Cancers | Rhabdoid Tumor |
| 2012 | $350,000.00 | Children's Oncology Group | Matching federal funds per child enrolled in Phase I clinical trials | |||
| 2012 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Craig Bassing | Targeting Bcl11b Haploin sufficient lymphoid tumors 6 | Blood Cancer | Lymphoma |
| 2012 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Edward Attiyeh | Xpo1 Inhibition in neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jed Nuchtern | Genomic anatomy of chemotherapy-resistant neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Immunotherapy of neuroblastoma with dual-specific Nkt cells | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Richard Gilbertson | Rapid and accurate diagnosis of Medolloblastoma subtypes in trials | Brain Tumors | Medolloblastoma |
| 2011 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Michael LaQuaglia | Phase I trial of Hepatic Artery Infusion/neuroblastoma tumors in the liver | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $25,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | A safe, potent Saponin adjuvant for Gd2 conjugated vaccine for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2011 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Kimberly Stegmaier | Validation of fak therapeutic target in Ewings sarcoma | Solid and Bone Cancers | Ewings sarcoma |
| 2011 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. George | Development of dendritic call vaccine against Alk-Positive | Solid and Bone Cancers | Neuroblastoma and others |
| 2011 | $100,000.00 | Children's Hospital of Philadelphia | Dr. M. Weiss | Modeling juvenile myelomonocytic Leukemia patient Ips cells | Blood Cancer | Leukemia |
| 2011 | $100,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Molecular oncology for pediatric cancers | Solid and Bone Cancers | Neuroblastoma |
| 2010 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jack Meng-Fen Su | Therapy efficacy study for newly diagnosed brainstem gliomas | Brain Tumors | Diffuse intrinsic pontine glioma (DIPG) |
| 2010 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Shohet | Therapy for relapsed neuroblastoma. P13k/Aktm tor pathway inhibition | Solid and Bone Cancers | Neuroblastoma |
| 2010 | $100,000.00 | St Jude Children's Research Hospital | Dr. Deepa Bhojwani | CD-20 targeted immunotherapy for relapsed childhood neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2010 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy, 2nd round of funding | Solid and Bone Cancers | Neuroblastoma |
| 2010 | $100,000.00 | Children's Hospital Of Philadelphia | Dr. Stephen Grupp | Engineered T Cell Therapy For Recurrent Neuroblastoma & B Cell Malignancies | Solid and Bone Cancers | Neuroblastoma |
| 2010 | $100,000.00 | Children's Hospital Of Philadelphia | Dr. Michael Hogarty | Sirna based Kimome screen to id Mcl1 antagonists for resistant Tumors | ||
| 2009 | $85,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Karen Rabin | Novel therapy using JAK-STAT pathway inhibitors in childhood leukemias | Blood Cancer | Leukemia |
| 2009 | $150,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Chrystal Louis | A phase I/II study using allogenic tumor cell vaccination with oral metronomic cytoxan in patients with high-risk neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
| 2009 | $100,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma |
| 2008 | $400,000.00 | Memorial Sloan-Kettering Cancer Center | Dr. Nai-Kong Cheung | Hu3f8 antibody treatment for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |